The financial costs of anticipatory prescribing : A retrospective observational study of prescribed, administered and wasted medications using community clinical records
BACKGROUND: The prescribing of injectable end-of-life anticipatory medications ahead of possible need is recommended best practice. The financial costs of these medications have been little studied.
AIM: To identify the costs of anticipatory medications prescribed, used and not used for patients approaching the end-of-life at home and in residential care.
DESIGN: Retrospective observational study using general practitioner and community nursing clinical records.
SETTING/PARTICIPANTS: Data were collected from eleven general practitioner practices using the records of the 30 most recent deaths per practice. Patients were aged 18+ and died between 2017 and 2019 from any cause except trauma, sudden death or suicide.
RESULTS: Anticipatory medications were prescribed to 167/329 patients, of which 164 were included in the analysis. Costs (GBP) were analysed both at patient-level and drug-level. Median anticipatory prescription cost was £43.17 (IQR: £38.98-£60.47, range £8.76-£229.82). Median administered (used) drug cost was £2.16 (IQR: £0.00-£12.09, range £0.00-£83.14). Median unused (wasted) drug cost was £41.47 (IQR: £29.15-£54.33, range £0.00-£195.36). Prescription, administered and unused costs were significantly higher for the 59 patients prescribed an anticipatory syringe driver. There were wide variations in the unused costs of individual drugs; Haloperidol and Cyclizine contributed 49% of total unused costs.
CONCLUSION: The costs of prescribed and unused anticipatory medications were higher than previously reported but remain modest. Usage of prescriptions was lower than previously documented. There may be scope to reduce the quantity of vials that are routinely prescribed without adversely affecting care; further research is needed to investigate this possibility.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Palliative medicine - 37(2023), 10 vom: 10. Dez., Seite 1554-1561 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morgan, Lloyd [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticipatory medications |
|---|
| Anmerkungen: |
Date Completed 20.11.2023 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/02692163231198372 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363105271 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363105271 | ||
| 003 | DE-627 | ||
| 005 | 20240210232727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/02692163231198372 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363105271 | ||
| 035 | |a (NLM)37817429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morgan, Lloyd |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The financial costs of anticipatory prescribing |b A retrospective observational study of prescribed, administered and wasted medications using community clinical records |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The prescribing of injectable end-of-life anticipatory medications ahead of possible need is recommended best practice. The financial costs of these medications have been little studied | ||
| 520 | |a AIM: To identify the costs of anticipatory medications prescribed, used and not used for patients approaching the end-of-life at home and in residential care | ||
| 520 | |a DESIGN: Retrospective observational study using general practitioner and community nursing clinical records | ||
| 520 | |a SETTING/PARTICIPANTS: Data were collected from eleven general practitioner practices using the records of the 30 most recent deaths per practice. Patients were aged 18+ and died between 2017 and 2019 from any cause except trauma, sudden death or suicide | ||
| 520 | |a RESULTS: Anticipatory medications were prescribed to 167/329 patients, of which 164 were included in the analysis. Costs (GBP) were analysed both at patient-level and drug-level. Median anticipatory prescription cost was £43.17 (IQR: £38.98-£60.47, range £8.76-£229.82). Median administered (used) drug cost was £2.16 (IQR: £0.00-£12.09, range £0.00-£83.14). Median unused (wasted) drug cost was £41.47 (IQR: £29.15-£54.33, range £0.00-£195.36). Prescription, administered and unused costs were significantly higher for the 59 patients prescribed an anticipatory syringe driver. There were wide variations in the unused costs of individual drugs; Haloperidol and Cyclizine contributed 49% of total unused costs | ||
| 520 | |a CONCLUSION: The costs of prescribed and unused anticipatory medications were higher than previously reported but remain modest. Usage of prescriptions was lower than previously documented. There may be scope to reduce the quantity of vials that are routinely prescribed without adversely affecting care; further research is needed to investigate this possibility | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticipatory prescribing | |
| 650 | 4 | |a anticipatory medications | |
| 650 | 4 | |a end of life care | |
| 650 | 4 | |a home palliative care | |
| 650 | 4 | |a medication costs | |
| 650 | 4 | |a palliative care | |
| 650 | 4 | |a palliative medicine kit | |
| 650 | 4 | |a terminal care | |
| 700 | 1 | |a Barclay, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Massou, Efthalia |e verfasserin |4 aut | |
| 700 | 1 | |a Bowers, Ben |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Palliative medicine |d 1996 |g 37(2023), 10 vom: 10. Dez., Seite 1554-1561 |w (DE-627)NLM074816403 |x 1477-030X |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:10 |g day:10 |g month:12 |g pages:1554-1561 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/02692163231198372 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 10 |b 10 |c 12 |h 1554-1561 | ||